Alpha-gal Syndrome (AGS) Clinical Trials

Find Alpha-gal Syndrome (AGS) Clinical Trials Near You

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13)

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a multisite, randomized, double-blind, controlled cross-over trial with detailed characterization of participants with varying clinical sub-phenotypes of Alpha-gal Syndrome (AGS) who are then evaluated by oral food challenges with alpha-gal Knock Out (KO) pork versus Wild Type (WT) pork. Each participant will serve as their own control and ingest both alpha-gal-KO and WT pork on different days, with a minimum of an 8-day washout period between oral food challenges. The primary objective is to determine whether the odds of positive challenges among participants with suspected alpha-gal syndrome are lower with alpha-gal Knock Out (KO) pork as compared to Wild Type (WT) pork during Double Blind Food Challenge (DBFC)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 50
Healthy Volunteers: f
View:

• Able to understand and provide informed consent and/or have a parent or guardian able to understand and provide informed consent. Participants 12-17 years old must be able to provide assent

• Participants who are willing to complete study procedures and follow-up

• Have clinical history consistent with Alpha-gal Syndrome (AGS)

• Have alpha-gal-specific Immunoglobin E (IgE) \>= 0.1KU/L at screening

• Report reaction consistent with AGS within the previous 24 months (prior to enrollment)

• If with reproductive potential, agree to be abstinent or use an US Food and Drug Administration (FDA) approved method of birth control for the duration of the study

• Willing to be trained on the proper use of a device for the self-administration of epinephrine (i.e., autoinjector or intra-nasal spray) and willing to have two doses available for the duration of the study

Locations
United States
Arkansas
Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology
NOT_YET_RECRUITING
Little Rock
North Carolina
North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
NOT_YET_RECRUITING
Chapel Hill
Tennessee
Vanderbilt University Medical Center: Division of Pediatric Allergy, Immunology, and Pulmonary Medicine
RECRUITING
Nashville
Virginia
University of Virginia Health System: Division of Asthma & Immunology
NOT_YET_RECRUITING
Charlottesville
Time Frame
Start Date: 2026-09-21
Estimated Completion Date: 2032-10-30
Participants
Target number of participants: 160
Treatments
Experimental: Sequence 1: KO, then WT
Each participant will serve as their own control and undergo a DBFC to alpha-gal KO pork, followed by a minimum of a 8-day washout period, then a DBFC to WT pork.
Experimental: Sequence 2: WT, then KO
Each participant will serve as their own control and undergo a DBFC to WT pork, followed by a minimum of a 8-day washout period, then a DBFC to alpha-gal KO pork.
Related Therapeutic Areas
Sponsors
Collaborators: Allergy & Asthma Statistical and Clinical Coordinating Center: Rho, Inc, Consortium for Food Allergy Research (CoFAR)
Leads: National Institute of Allergy and Infectious Diseases (NIAID)

This content was sourced from clinicaltrials.gov